Skip to main content
Veterinary Medicines

PROGRAM Plus

Not authorised
  • Milbemycin oxime
  • Lufenuron

Product identification

Medicine name:
PROGRAM Plus
Program Plus 11,5 mg/230 mg, überzogene Tablette für Hunde
Active substance:
  • Milbemycin oxime
  • Lufenuron
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Milbemycin oxime
    11.50
    milligram(s)
    /
    1.00
    Tablet
  • Lufenuron
    230.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB51
Authorisation status:
  • Surrendered
Authorised in:
  • Austria
Package description:
  • Carton container containing 8 pentagonal tablets in PVDC/PVC blisters, thermosealed with aluminium foil, boxed in a free-opening, labelled carton
  • Carton container containing 6 pentagonal tablets in PVDC/PVC blister, thermosealed with aluminium foil, boxed in a free-opening, labelled carton

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Elanco GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Elanco France S.A.S
Responsible authority:
  • Austrian Agency For Health And Food Safety
Authorisation number:
  • 8-00501
Date of authorisation status change:
Reference member state:
  • Italy
Procedure number:
  • IT/V/0106/003

Documents

Summary of Product Characteristics

English (PDF)
Published on: 14/02/2022
Download
German (PDF)
Published on: 25/08/2021

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 4/03/2019

Labelling

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 27/01/2020
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."